<DOC>
	<DOC>NCT01377194</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).</brief_summary>
	<brief_title>Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Men and women, 1875 years old Currently meet the DSMIVTR criteria for Major Depressive Disorder The patient's current depressive episode must be at least 6 weeks in duration Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control. Patients who are considered a suicide risk Patients with a history of meeting DSMIVTR criteria for a. any manic or hypomanic episode b. schizophrenia or any other psychotic disorder c. obsessivecompulsive disorder.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>